Group 1 - WanTai Biologics' nine-valent HPV vaccine has been approved for market launch, targeting women aged 9-45, enhancing the company's product line and core competitiveness [3] - Hainan Huatie is planning to issue shares overseas and list on the Singapore Exchange to advance its international strategy and enhance brand influence [4] - HeXing Co. clarified that it is not involved in "unmanned logistics vehicles" or "autonomous driving" businesses, despite market speculation [5] Group 2 - Maiwei Co. intends to invest 100 million yuan in a fund focused on growth-stage companies in the new energy and semiconductor sectors [6] - SuKun Agricultural Development plans to acquire 28.75% of JinTaiSun Grain and Oil for 178 million yuan, increasing its stake to 80% [7] - CITIC Construction Investment has received approval to issue up to 8 billion yuan in technology innovation corporate bonds to professional investors [8] Group 3 - Beibu Gulf Port reported a cargo throughput of 30.86 million tons in May, a year-on-year increase of 6.43%, with a cumulative throughput of 143 million tons for the year, up 12.96% [10] - Kweichow Moutai has repurchased 3.31 million shares for a total expenditure of 5.1 billion yuan by the end of May [12] - Contemporary Amperex Technology has repurchased 6.64 million A-shares for a total of 1.55 billion yuan by May 31 [13] - Jialong Co. has adjusted its share repurchase price ceiling from 2.20 yuan to 3.50 yuan due to recent stock price increases [14] Group 4 - China Electric Power Construction's subsidiary has won a 6.282 billion yuan energy storage project contract [16] - Xili Technology has been awarded a 1.31 billion yuan project by the State Grid for smart energy meters [17]

Core Points - The Guangdong Province has officially announced the "Regulations on Promoting High-Quality Development of the Marine Economy," which will take effect on July 1, 2025, aimed at addressing prominent issues in marine economic development and enhancing institutional support [1][2] Group 1: Legislative Overview - The regulation consists of seven chapters and fifty-three articles, focusing on five key areas: industrial development, technological innovation, green development, open cooperation, and service guarantees [1] - The marine production value of Guangdong Province reached 20,022.5 billion yuan in 2024, accounting for 14.1% of the regional GDP, marking the province's marine economy as the largest in the country for 30 consecutive years [1] Group 2: Industrial Development - The second chapter of the regulation highlights various marine industries, including marine electronic equipment, marine engineering equipment manufacturing, marine pharmaceuticals, offshore wind power, and modern fisheries [2] - Specific provisions encourage breakthroughs in key technologies for marine engineering equipment and support the development of new marine equipment such as submersibles and underwater robots [2] Group 3: Data and Resource Management - The regulation mandates the establishment of a marine data space and emphasizes the efficient flow of marine data elements through improved data sharing and management [3] - It also requires the government to promote layered rights management of marine areas to optimize the use of marine spatial resources [3] Group 4: Implementation and Support - The Guangdong Provincial Development and Reform Commission is designated as the main authority for overseeing the marine economy, tasked with developing related policy documents and planning for the "14th Five-Year Plan" [4] - The Natural Resources Department will lead the comprehensive implementation of the regulation, focusing on coastal planning and enhancing market-oriented allocation of marine resources [4]

证券研究报告 | 2025年06月03日 康方生物（09926.HK） HARMONi 临床达到 PFS 主要终点，国内外患者展现出一致的获益 |  | 公司研究·海外公司快评 | |  医药生物·生物制品 |  投资评级：优于大市（维持） | | --- | --- | --- | --- | --- | | 证券分析师： | 陈曦炳 | 0755-81982939 | chenxibing@guosen.com.cn | 执证编码：S0980521120001 | | 证券分析师： | 彭思宇 | 0755-81982723 | pengsiyu@guosen.com.cn | 执证编码：S0980521060003 | | 证券分析师： | 陈益凌 | 021-60933167 | chenyiling@guosen.com.cn | 执证编码：S0980519010002 | 事项： 公司合作伙伴 Summit 公告 HARMONi 临床达到 PFS 主要临床终点。 国信医药观点：1）HARMONi 是依沃西联合含铂双药化疗治疗 EGFR-TKI 治疗进展的 EGFRm NSCLC 的全球多 中 ...

一、全球市场占有率行业第一？ 文/梧桐兄弟 5月30日，五峰赤诚生物科技股份有限公司北交所IPO被宣布终止审核，直接原因是公司于5月20日申请撤回申请。赤诚生物IPO申报于2024年6月27日获得受理， 2024年7月24日收到首轮问询并完成了回复。 然而，2024年年度报告披露， 2024年公司归母扣非净利润却下滑至2,985.45万元。 公司主要从事水解单宁系列产品的研发、生产及销售业务，产品所需的主要原材料为五倍子和塔拉粉。报告期内，公司主要产品为单宁酸、没食子酸系列产品及 衍生化合物。 根据行业研究机构QYResearch发布的《2024-2030全球及中国单宁酸行业研究及十五五规划分析报告》及《2024-2030全球及中国没食子酸行业研究及十五五规划分 析报告》，2023年全球单宁酸及全球没食子酸市场规模分别约为11.61亿元、19.15亿元，公司及主要竞争对手在单宁酸市场及没食子酸市场的市场占有率情况如 下： | 公司名称 | 2023 年度全球市场占有率情况 | | | --- | --- | --- | | | 单宁酸市场 | 没食子酸市场 | | 张家界久瑞生物科技有限公司 | 5. 33% ...

[Table_Reportdate] 2025年06月03日 [table_invest] 超配 行 业 周 报 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 赖菲虹 S0630525050001 lfhong@longone.com.cn 联系人 付婷 futing@longone.com.cn [table_stockTrend] -25% -17% -8% 1% 10% 18% 27% 24-05 24-08 24-11 25-02 申万行业指数:医药生物(0737) 沪深300 ➢ 市场表现： 上周（05月26日-05月30日）医药生物板块整体上涨2.21%，在申万31个行业中排第 2位，跑赢沪深300指数3.29个百分点。年初至今，医药生物板块整体上涨6.61%，在申万 31个行业中排名第6位，跑赢沪深300指数9.02个百分点。当前医药生物板块PE估值为 27.98倍，处于历史中位水平，相对于沪深300的估值溢价为137%。子板块涨幅前三的为 化学制药(申万)、生物制品(申万)、医疗服务(申万)，涨幅分别为3.83%、3.14%、2.46%。 个股方面，上 ...

中国经济网北京6月1日讯北交所网站2025年5月30日披露关于终止对五峰赤诚生物科技股份有限公司(以 下简称"赤诚生物")公开发行股票并在北京证券交易所上市审核的决定。 北交所于2024年6月27日受理了赤诚生物提交的公开发行相关申请文件，并按照规定进行了审核。 陈赤清直接持有赤诚生物20.40%的股份，通过担任五峰得倍投资管理服务部(有限合伙)(以下简称"得倍 投资")执行事务合伙人而间接控制得倍投资持有的赤诚生物1.78%的股份，合计控制赤诚生物22.18%的 股份，且担任赤诚生物的董事长、法定代表人。 毛业富直接持有赤诚生物19.43%的股份，通过担任五峰倍农投资管理服务部(有限合伙)(以下简称"倍农 投资")执行事务合伙人而间接控制倍农投资持有的赤诚生物0.84%的股份，合计控制赤诚生物20.27%的 股份，且担任赤诚生物董事、总经理。毛业富的一致行动人，其配偶胡金兰及妹妹毛业琼分别直接持有 赤诚生物0.72%及4.42%的股份。毛业富及其一致行动人合计控制赤诚生物25.41%的股份。 陈赤清与毛业富为赤诚生物创始人，且通过上述股权安排合计控制赤诚生物47.58%的股份，系赤诚生 物控股股东及实际控制 ...

随着上市公司2024年年报与2025年一季报披露工作正式收官，5月以来，A股机构评级次数愈发频繁。 据证券时报·数据宝统计，5月内71家机构合计进行了5151次评级，共计1859只个股被券商研报给予"买入型"评级（包括买入、增持、强烈推荐、推荐）。 医药、食饮、电力设备行业 机构关注度较高 根据机构数量划分，上述个股中，共计316股获得5家及以上机构参与评级。从行业上看，这316股广泛分布于医药生物、食品饮料、电力设备等申万行 业，上榜个股数量均在30只以上；汽车和电子也有多股获评，数量均超过25只。 申万医药生物指数5月累计上涨6.42%，位于一级行业指数涨幅第二位。细分赛道中，化学制药、生物制品、医疗服务等涨幅靠前，均超过5%。 个股中，舒泰神以145.37%的月涨幅居首。公司属创新药领域，其控股子公司江苏贝捷泰的"注射用STSP-0601"进入国家药品监督管理局药品审评中心 （NMPA）"拟优先审评品种公示"，市场关注度较高。此外，龙头企业包括恒瑞医药、迈瑞医疗、药明康德等均录得不错的涨幅。 中信建投证券指出，"三医联动"顶层制度设计的改革措施已经逐步落地。医药领域的改革政策已进入常态化阶段；医保领域是 ...

Core Viewpoint - The latest statistics from the Ministry of Natural Resources indicate that China's marine GDP reached 2.5 trillion yuan in the first quarter of this year, reflecting a year-on-year growth of 5.7%, highlighting the accelerated construction of a modern marine industry system [1] Group 1: Marine Economic Development - China's marine economy has shown significant high-quality development, with the added value of emerging marine industries expected to grow by 7.2% in 2024, surpassing the overall marine GDP growth by 1.3 percentage points [2] - The number of automated container and bulk cargo terminals has reached the highest in the world, with operational efficiency at automated terminals maintaining a global lead [2] - The usage rate of clean energy in international hub ports has exceeded 60%, and the market share for new green ship orders has reached 78.5% [2] Group 2: Policy and Innovation - A joint guideline issued by the Ministry of Natural Resources and five other departments aims to promote the large-scale utilization of marine energy, focusing on resource potential assessment, technological innovation, open cooperation, and policy measures [2] - Guangdong Province has established the Greater Bay Area Marine Energy Innovation Alliance, exploring innovative models for marine energy development [2] Group 3: Technological Innovation - The development plan for marine technology emphasizes addressing real demands, focusing on key areas such as polar energy, bioresource development, clean energy for ports, high-end marine equipment, and marine biomedicine [3] - A mechanism for integrated development of production, education, research, and application is being established to enhance the proportion of marine technology R&D projects in fiscal spending [3] Group 4: Industry Structure - Traditional industries are being upgraded through the integration of digital technologies such as IoT, big data, AI, and virtual simulation, particularly in marine oil and gas, shipbuilding, transportation, and fisheries [3] - The development of strategic and leading emerging industries is being promoted, including offshore wind power, deep-sea engineering equipment manufacturing, marine pharmaceuticals, and new marine materials [3] Group 5: Talent Development - Strengthening the talent cultivation and recruitment mechanism in marine sectors, implementing interdisciplinary training plans, and collaborating with national laboratories and leading tech enterprises to develop marine technology experts [4] - International cooperation is being enhanced through the establishment of overseas educational institutions and joint research efforts, with a focus on attracting marine technology innovation talents and seafarers [4]

截至2025年5月30日收盘，智翔金泰（688443）报收于29.74元，较上周的27.6元上涨7.75%。本周，智 翔金泰5月30日盘中最高价报29.9元。5月26日盘中最低价报25.75元。智翔金泰当前最新总市值109.05亿 元，在生物制品板块市值排名24/50，在两市A股市值排名1422/5146。 本周关注点 机构调研要点 公司正在积极筹备赛立奇单抗注射液（金立希）的国家医保谈判工作，争取早日进入医保，惠及更多患 者。 GR1802注射液中重度特应性皮炎适应症于2024年8月完成III期临床试验入组，目前处于III期临床试验阶 段。公司将积极推动在研产品开发工作，根据进展情况履行信息披露义务。 公司将根据实际情况综合考虑产品合作事项，并依据信息披露规则履行信息披露责任。 公司正在积极筹备赛立奇单抗注射液（金立希）的国家医保谈判工作。公司积极推动跟国内头部经销商 与平台的战略合作，利用优质渠道资源快速实现产品市场覆盖和渗透。公司将继续聚焦主业，提升经营 效率和盈利能力，推动公司提升投资价值，增强投资者回报。 公司组建了一支约200人的商业化团队，积极推动赛立奇单抗注射液的商业化。 公司GR2001注射 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Zhifei Green Bamboo, has received a "Notice of Acceptance" from the National Medical Products Administration for the production registration of the ACYW135 group meningococcal polysaccharide conjugate vaccine (quadrivalent meningococcal vaccine) [1] Group 1: Product Development - Currently, there is only one quadrivalent meningococcal vaccine available in the domestic market [1] - If the vaccine is approved for market sale, it will create a synergistic effect with the company's existing meningococcal vaccine products, strengthening the company's vaccine portfolio [1] Group 2: Market Position - The approval will enhance the company's market position and competitiveness in the meningococcal vaccine sector [1] Group 3: Financial Impact - The acceptance of the production registration application will not have a significant impact on the company's short-term performance due to the high investment, long development cycle, and associated risks in drug development [1]